Trade Report: The Analysts Issue Forecasts for Astrazeneca PLC’s Q3 2016 Earnings (AZN)

The Analysts Issue Forecasts for Astrazeneca PLC’s Q3 2016 Earnings (AZN)

Astrazeneca PLC (NYSE:AZN) – Stock analysts at Jefferies Group issued their Q3 2016 earnings estimates for shares of Astrazeneca PLC in a research report issued to clients and investors on Thursday. Jefferies Group analyst J. Holford forecasts that the brokerage will post earnings of $0.51 per share for the quarter. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.37 EPS, FY2019 earnings at $2.85 EPS and FY2020 earnings at $3.41 EPS.

A number of other research firms have also recently issued reports on AZN. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Piper Jaffray Cos. started coverage on Astrazeneca PLC in a research report on Friday, September 23rd. They set an “overweight” rating on the stock. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 10th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, September 28th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. Astrazeneca PLC has a consensus rating of “Hold” and an average target price of $37.56.

Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.16% on Friday, hitting $30.79. The stock had a trading volume of 1,794,964 shares. The firm has a 50 day moving average price of $32.95 and a 200-day moving average price of $30.86. The company has a market cap of $77.90 billion, a price-to-earnings ratio of 35.19 and a beta of 0.75. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company earned $1.21 earnings per share.

Several large investors have recently made changes to their positions in the company. Forester Capital Management LTD increased its stake in shares of Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. First Interstate Bank increased its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp increased its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp increased its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC increased its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. Institutional investors own 11.39% of the company’s stock.

Astrazeneca PLC Company Profile

Related posts

Leave a Comment